Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 55 years or older at the time of joining the trial.
• People who have already had genetic testing confirming they carry at least one copy of the APOE ε4 gene variant (this can be from a doctor's test, a research study, or even a consumer DNA test such as 23andMe).
• People who already have whole-genome sequencing (a detailed type of DNA test) on file and are willing to share those data files with the study team, OR people who have results from a different type of genetic array test covering Alzheimer's-related genes and are willing to share those (whether array data is suitable will be assessed case by case by the trial team). Note: the trial does not carry out these genetic tests — they must already be completed before joining.
• People who are currently thinking and remembering normally, or who have only very mild cognitive changes, with no existing diagnosis of dementia (this is assessed using digital cognitive tests and/or a brief thinking test).
• People who do not currently meet criteria for Alzheimer's-related mild cognitive impairment, based on blood or spinal fluid levels of a protein called pTau217 being below a certain threshold (confirm with trial site).
• People who are able to understand and agree to take part in the study, and who can complete study activities such as clinic visits, thinking tests, and providing small biological samples.
• People who are willing to wear or carry digital monitoring devices such as a smartwatch, an Oura Ring sleep tracker, or a smartphone app, and to take part in app-based thinking and speech tests.
• People who are willing to sign forms allowing the study team to access their existing genetic data and relevant medical records for use in the study.

Who may not be able to join:

• People who already have a diagnosis of dementia of any kind at the time of joining.
• People with a significant neurological condition that the trial doctor believes could affect thinking test results or study outcomes — for example, Parkinson's disease, a stroke with lasting neurological effects, or epilepsy with frequent seizures.
• People with a major psychiatric condition, such as uncontrolled severe depression or schizophrenia, that the trial doctor believes would significantly affect participation or the reliability of results.
• People with a serious or unstable medical condition expected to limit life expectancy to less than approximately three years, such as unstable heart, liver, or kidney disease.
• People who have taken an investigational drug or an Alzheimer's disease-modifying treatment within the six months before joining, if the trial team determines this could affect test results or biomarker readings.
• People who are unable or unwilling to use the required digital monitoring tools and apps.
• People who do not have prior genetic documentation confirming at least one APOE ε4 allele, who have no existing whole-genome sequencing or suitable genetic array data on file, or who are unwilling to share their existing genetic and medical record data with the study team.
• People who already meet criteria for mild cognitive impairment related to Alzheimer's disease, based on elevated pTau217 levels in blood or spinal fluid.
• Children, people who are pregnant, and prisoners are not included in this trial.

Important: Always verify eligibility with the trial site directly before applying.